Stealth Wins Adcomm’s Unexpected Support for Ultra-Rare Disease Drug Candidate

Despite substantial variability in the presented data and no well-controlled trial, the FDA advisory committee voted in favor of Stealth BioTherapeutics’ Barth syndrome therapy elamipretide, citing the urgent unmet need.